Simulations Plus, Inc. (SLP): Completion of Acquisition or Disposition of Assets
Simulations Plus, Inc. (SLP) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. 1 Exhibit 99.1 Simulations Plus Announces Completion of Acquisition by Altaris RESEARCH TRIANGLE PARK, NC, October 6, 2026 – Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that adva
How this was made
The 30-second read
Why it matters
The delisting ends public trading, delivering cash to shareholders and consolidating two software platforms under Altaris ownership.
Market read
Primary M&A disclosure with immediate cash distribution; relevant for shareholders and biotech software sector.
What to watch
Future integration benefits for Altaris‑owned CCG could create upside for related biotech software stocks.
Background
Simulations Plus, a Nasdaq‑listed provider of AI‑driven drug‑development software, completed its acquisition by Altaris and will be merged with Chemical Computing Group.
Ticker impact
SEC 8‑K reports completion of Simulations Plus acquisition by Altaris, cash $18.50 per share and delisting from Nasdaq.
likely pressure as the ticker is removed, but cash distribution is positive for existing holders
The acquisition is final and the company is now private; no further equity trading will occur.
Market effects
Consolidation in the drug‑discovery software niche may pressure peers.
Limited to U.S. biotech investors holding SLP shares.
Minimal; the deal is private‑equity driven without broader market ripple.
Counterpoint
Investors could view the cash payout as a modest return versus potential upside if the company remained public.
Key entities
- companySimulations Plus, Inc.
Acquired by Altaris; former Nasdaq ticker SLP.
- investment firmAltaris, LLC
Private‑equity sponsor completing the acquisition.


